Work recently published in the “European Journal of Pharmacology" by Dr. Mélanie Barbosa, Dr. Ryan D. Kruschel et al., has demonstrated the potential of two isoquinolinequinone N-oxides (RK2 and RK3) as promising candidates for the next stages of drug development against multidrug resistant cancers, specifically linked to the overexpression of ABCB1. This work is the result of a collaboration of Prof. Helena Vasconcelos from i3S, University of Porto - Portugal, with Prof. Florence McCarthy, from the School of Chemistry, University College Cork - Ireland.
